PL3661954T3 - Muteiny interleukiny 21 i sposoby leczenia - Google Patents

Muteiny interleukiny 21 i sposoby leczenia

Info

Publication number
PL3661954T3
PL3661954T3 PL18759207T PL18759207T PL3661954T3 PL 3661954 T3 PL3661954 T3 PL 3661954T3 PL 18759207 T PL18759207 T PL 18759207T PL 18759207 T PL18759207 T PL 18759207T PL 3661954 T3 PL3661954 T3 PL 3661954T3
Authority
PL
Poland
Prior art keywords
muteins
interleukin
treatment
Prior art date
Application number
PL18759207T
Other languages
English (en)
Inventor
Khaled M.K.Z. Ali
Neeraj Jagdish Agrawal
Gunasekaran Kannan
Ian Foltz
Zhulun Wang
Daren BATES
Marissa Mock
Shunseke TAKENAKA
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of PL3661954T3 publication Critical patent/PL3661954T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18759207T 2017-08-03 2018-08-03 Muteiny interleukiny 21 i sposoby leczenia PL3661954T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762540692P 2017-08-03 2017-08-03
US201862616733P 2018-01-12 2018-01-12
EP18759207.6A EP3661954B1 (en) 2017-08-03 2018-08-03 Interleukin-21 muteins and methods of treatment
PCT/US2018/045105 WO2019028316A1 (en) 2017-08-03 2018-08-03 INTERLEUKIN-21 MUTÉINS AND METHODS OF TREATMENT

Publications (1)

Publication Number Publication Date
PL3661954T3 true PL3661954T3 (pl) 2022-05-16

Family

ID=63350603

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18759207T PL3661954T3 (pl) 2017-08-03 2018-08-03 Muteiny interleukiny 21 i sposoby leczenia

Country Status (37)

Country Link
US (2) US11541103B2 (pl)
EP (2) EP3661954B1 (pl)
JP (2) JP7079171B2 (pl)
KR (2) KR20220092652A (pl)
CN (2) CN111164100B (pl)
AU (2) AU2018311079B2 (pl)
BR (2) BR122021015266B1 (pl)
CA (1) CA3071376A1 (pl)
CL (3) CL2020000252A1 (pl)
CO (1) CO2020001113A2 (pl)
CR (1) CR20200099A (pl)
CY (1) CY1125429T1 (pl)
DK (1) DK3661954T3 (pl)
ES (2) ES2910969T3 (pl)
HR (1) HRP20220404T1 (pl)
HU (1) HUE058233T2 (pl)
IL (2) IL272137B2 (pl)
JO (1) JOP20200020B1 (pl)
LT (1) LT3661954T (pl)
MA (1) MA56289B1 (pl)
MX (2) MX2020001328A (pl)
MY (1) MY195974A (pl)
PE (2) PE20250757A1 (pl)
PH (1) PH12020500231A1 (pl)
PL (1) PL3661954T3 (pl)
PT (1) PT3661954T (pl)
RS (1) RS63101B1 (pl)
SA (2) SA522432917B1 (pl)
SG (1) SG11202000821SA (pl)
SI (1) SI3661954T1 (pl)
SM (1) SMT202200162T1 (pl)
TN (1) TN2020000015A1 (pl)
TW (3) TWI844073B (pl)
UA (1) UA130113C2 (pl)
UY (1) UY37829A (pl)
WO (1) WO2019028316A1 (pl)
ZA (2) ZA202001251B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11059892B2 (en) 2017-08-11 2021-07-13 Research Development Foundation Engineered antibody Fc variants for enhanced serum half life
WO2019207942A1 (ja) * 2018-04-27 2019-10-31 OTA Takayo 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー
WO2020023702A1 (en) * 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3123338A1 (en) * 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020172528A1 (en) * 2019-02-22 2020-08-27 Anwita Biosciences, Inc. Albumin binding antibodies and use thereof
JP2022530667A (ja) * 2019-04-30 2022-06-30 ターゲット ディスカバリー マージャー サブ トゥー， エルエルシー がん関連抗体組成物および使用方法
MX2022005566A (es) * 2019-11-08 2022-07-19 Amgen Inc Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.
WO2021092719A1 (zh) * 2019-11-11 2021-05-20 王盛典 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
CN111087473B (zh) * 2019-12-11 2022-06-14 上海百英生物科技有限公司 一种SIRPa-Fc-IL21融合蛋白及其应用
JP7512433B2 (ja) 2020-05-26 2024-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｄ－１抗体
CN111925990B (zh) * 2020-09-02 2022-08-26 北京立康生命科技有限公司 一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4232072A4 (en) * 2020-10-26 2024-09-04 Neptune Biosciences LLC ORTHOGONAL CYTOKINE/IL-21 RECEPTOR SYSTEMS
CA3201573A1 (en) * 2020-12-09 2022-06-16 Ivana DJURETIC Targeted cytokine construct for engineered cell therapy
US20240043487A1 (en) * 2020-12-23 2024-02-08 Innovent Biologics (Suzhou) Co., Ltd. Interleukin-21 mutant and use thereof
CA3207652A1 (en) 2021-03-26 2022-09-29 Stephanie Cornen Cytokine anchors for nkp46-binding nk cell engager proteins
MX2023011964A (es) * 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
JP2024516401A (ja) 2021-04-27 2024-04-15 アムジエン・インコーポレーテツド 温度の使用による非対称抗体の製品品質の調節
GB2638094A (en) * 2021-05-19 2025-08-13 Asher Biotherapeutics Inc Il-21 Polypeptides And Targeted Constructs
JP2024521405A (ja) 2021-06-09 2024-05-31 イナート・ファルマ・ソシエテ・アノニム Ｎｋｐ４６、サイトカイン受容体、腫瘍抗原およびｃｄ１６ａに結合する多特異性タンパク質
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CA3227990A1 (en) * 2021-08-06 2023-02-09 Amgen Inc. Isolation of therapeutic protein
JP2024536837A (ja) * 2021-09-24 2024-10-08 バイオンシステムズ インコーポレイテッド Ｐｄ－１とｉｌ－２１とを含む融合タンパク質二量体、及びその使用
WO2023052846A2 (en) * 2021-09-30 2023-04-06 Ildong Pharmaceutical Co., Ltd. Immunocytokine containing il-21r mutein
EP4511054A2 (en) * 2022-04-20 2025-02-26 Neptune Biosciences LLC Orthogonal il-21 receptor/cytokine systems
AU2023264616A1 (en) * 2022-05-05 2024-10-24 Amgen Inc. Heteromultimer binding dll3 and cd3
KR102796245B1 (ko) * 2022-05-10 2025-04-18 아주대학교산학협력단 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도
AU2023296675A1 (en) * 2022-06-29 2024-10-31 Beijing Neox Biotech Limited Il-21 polypeptides and methods of use
CN117645669B (zh) * 2022-08-29 2024-11-01 星奕昂(上海)生物科技有限公司 具有膜结合型il-21的免疫细胞及其制法和应用
CN117645661A (zh) * 2022-09-02 2024-03-05 北京志道生物科技有限公司 一种聚乙二醇修饰的il-21衍生物及其应用
WO2024228173A2 (en) * 2023-05-04 2024-11-07 Peptone, Ltd. Engineered cytokines and uses thereof
WO2025191133A1 (en) * 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
EP4644413A1 (en) * 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2025251226A1 (en) 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell
EP4671273A1 (en) * 2024-06-26 2025-12-31 Anaveon AG INTERLEUKIN 21 PROXIMITY ACTIVATED
WO2026003219A1 (en) * 2024-06-26 2026-01-02 Anaveon AG Proximity activated interleukin 21
CN118546233B (zh) * 2024-07-30 2024-10-18 成都微芯新域生物技术有限公司 白介素-21突变体及其应用
CN119954929B (zh) * 2025-02-12 2025-12-02 华润生物医药有限公司 Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途
CN119978098A (zh) * 2025-02-12 2025-05-13 华润生物医药有限公司 Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途
CN119954928B (zh) * 2025-02-12 2025-12-02 华润生物医药有限公司 Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
CA2320193A1 (en) 1998-02-10 1999-08-19 Welfide Corporation Controlled release preparation
TR200003087T2 (tr) 1998-04-21 2001-02-21 Micromet Ag Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
JP2003535565A (ja) 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション 新生物疾患の治療に有用な組換え単純ヘルペスウイルス
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000054795A1 (en) 1999-03-15 2000-09-21 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CN1418255A (zh) 2000-01-21 2003-05-14 拜奥维克斯有限公司 用于基因治疗的疱疹病毒毒株
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7749745B2 (en) 2001-03-27 2010-07-06 Georgetown University Viral vectors and their use in therapeutic methods
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
AU2002336676A1 (en) 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
ES2307832T3 (es) 2001-12-03 2008-12-01 Amgen Fremont Inc. Clasificacion de anticuerpos basada en las caracteristicas de union.
ATE547430T1 (de) 2002-01-18 2012-03-15 Zymogenetics Inc Multimere des cytokinrezeptors zcytor17
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
AU2003243415A1 (en) 2002-06-07 2003-12-22 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CN1513993A (zh) * 2002-12-31 2004-07-21 北京博泰迪生物工程科技开发有限公司 中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
CA2538083A1 (en) 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
PL1673398T3 (pl) 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
JP2008533147A (ja) 2005-03-14 2008-08-21 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
RU2412199C2 (ru) 2005-04-18 2011-02-20 Ново Нордиск А/С Варианты ил-21
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
CA2632218A1 (en) 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
PL1963369T3 (pl) 2005-11-28 2013-10-31 Zymogenetics Inc Antagoniści IL-21
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
BRPI0709787A2 (pt) 2006-05-08 2011-03-29 Philogen Spa citocinas com anticorpos alvejados para terapia
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
EP2109620B1 (en) 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
EP4059964A1 (en) 2007-04-03 2022-09-21 Amgen Research (Munich) GmbH Cross-species-specific binding domain
FI2155783T4 (fi) 2007-04-03 2022-12-15 Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
CN101657190B (zh) 2007-04-19 2013-09-11 东亚制药株式会社 一种适用于对葡萄糖控制肽进行控释的可生物降解的微球组合物及其制剂
EP3103813A1 (en) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
JP6126782B2 (ja) 2008-10-01 2017-05-10 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
EP2406282A1 (en) * 2009-03-11 2012-01-18 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
CN102573922B (zh) 2009-08-17 2015-08-05 罗切格利卡特公司 靶向性免疫缀合物
ES2700230T3 (es) 2009-10-30 2019-02-14 Albumedix Ltd Variantes de albúmina
PT2542590T (pt) 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
AU2012215572A1 (en) 2011-02-10 2013-05-02 Roche Glycart Ag Improved immunotherapy
JP2014517683A (ja) 2011-03-11 2014-07-24 アムジェン インコーポレイテッド 治療抗体を改善する相関突然変異分析の方法
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP6430828B2 (ja) 2011-05-05 2018-11-28 アルブミディクス リミティド アルブミン変異体
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US20130028882A1 (en) 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
DK2753355T3 (en) 2011-09-08 2019-01-28 Univ New York ONCOLYTIC HERP SIMPLEX VIRUSES AND THERAPEUTIC APPLICATIONS THEREOF
EP3559049B1 (en) * 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
WO2013096732A2 (en) 2011-12-23 2013-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing viral diseases by blocking interleukin-21
WO2013109904A1 (en) 2012-01-19 2013-07-25 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
MY174248A (en) 2012-04-30 2020-04-01 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
WO2013169734A1 (en) 2012-05-07 2013-11-14 Amgen Inc. Anti-erythropoietin antibodies
WO2013169693A1 (en) * 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
EP3434695B1 (en) 2012-08-07 2020-12-02 Roche Glycart AG Improved immunotherapy
RU2670063C2 (ru) 2012-11-08 2018-10-17 Альбумедикс А/С Варианты альбумина
WO2014139468A1 (en) 2013-03-15 2014-09-18 Admark Healthcare, Llc Fusion protein molecules and method of use
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
WO2015000585A1 (en) 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
EP3019531A4 (en) 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunoglobulin fusion proteins and compositions thereof
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CA2935665A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
JP6416926B2 (ja) 2014-02-19 2018-10-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ガン標的化ｉｌ−１２免疫療法
SG10201913627TA (en) 2014-04-08 2020-03-30 Boston Pharmaceuticals Inc Binding molecules specific for il-21 and uses thereof
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP4382535A3 (en) 2014-12-15 2024-08-21 Washington University Compositions and methods for targeted cytokine delivery
CN107249633A (zh) 2014-12-19 2017-10-13 迈博太科公司 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法
EP3233120A4 (en) 2014-12-19 2018-05-30 Monash University Il-21 antibodies
KR20160113452A (ko) 2015-03-20 2016-09-29 (주)엘지하우시스 진공 단열재용 심재 및 진공단열재
GEAP202215554A (en) 2015-07-30 2022-06-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
US20180221503A1 (en) 2015-07-31 2018-08-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
EP4458417A3 (en) 2015-08-11 2025-02-19 Wuxi Biologics Ireland Limited Novel anti-pd-1 antibodies
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
PE20181092A1 (es) 2015-10-02 2018-07-09 Hoffmann La Roche Anticuerpos anti-pd1 y metodos de uso
JP2019500893A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
MA44146B1 (fr) * 2015-12-22 2023-10-31 Regeneron Pharma Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
DK3400293T4 (da) 2016-01-08 2023-08-28 Replimune Ltd Modificeret onkolytisk virus
WO2017123643A1 (en) 2016-01-11 2017-07-20 Flagship Pioneering, Inc. Methods and compositions for modulating thymic function
CA3011942A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
CN116063544A (zh) 2016-02-03 2023-05-05 安进研发（慕尼黑）股份有限公司 Bcma和cd3双特异性t细胞接合抗体构建体
KR20180117116A (ko) 2016-02-05 2018-10-26 워싱턴 유니버시티 표적화된 사이토카인 전달을 위한 조성물 및 방법들
JP6991979B2 (ja) 2016-02-05 2022-03-04 オリオニス バイオサイエンシズ ビーブイ Ｃｄ８結合物質
CA3017813C (en) 2016-03-17 2021-12-07 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
KR102389096B1 (ko) 2016-04-01 2022-04-25 암젠 인크 Flt3에 대한 키메라 수용체 및 이의 사용 방법
KR102211838B1 (ko) 2016-04-22 2021-02-03 임비라 컴퍼니 리미티드 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
CA3029426A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
RU2656181C1 (ru) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
AU2017305335B2 (en) 2016-08-01 2021-11-18 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
AU2017328309B2 (en) 2016-09-14 2020-10-15 Beijing Hanmi Pharm. Co., Ltd. Antibody specifically binding to PD-1 and functional fragment thereof
KR102273634B1 (ko) 2016-09-21 2021-07-07 씨스톤 파마슈티컬즈 예정 사멸 1(pd-1)에 대한 신규한 단일클론성 항체
EP3515472A4 (en) 2016-09-23 2020-04-29 OncoSec Medical Incorporated MODULATION OF REACTIONS ON CHECKPOINT INHIBITOR THERAPY
MX2019004834A (es) 2016-11-02 2019-06-20 Jounce Therapeutics Inc Anticuerpos de pd-1 y usos de estos.
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN107082812B (zh) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
JP7426825B2 (ja) 2017-04-03 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート
KR20200037781A (ko) 2017-07-03 2020-04-09 토크 테라퓨틱스, 인코포레이티드 면역자극 융합 분자 및 이의 용도
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
US20210024631A1 (en) 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
BR112020020857A2 (pt) 2018-04-10 2021-01-19 Amgen Inc. Receptores quiméricos para dll3 e métodos de seu uso
JP2021527706A (ja) 2018-06-18 2021-10-14 アンウィタ バイオサイエンシス， インク． 抗メソテリンコンストラクト及びその使用
WO2020065096A1 (en) 2018-09-28 2020-04-02 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
BR112021012027A2 (pt) 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula bifuncional direcionada contra pd-1 humano

Also Published As

Publication number Publication date
MY195974A (en) 2023-02-27
RS63101B1 (sr) 2022-04-29
ES2975221T3 (es) 2024-07-04
US20190046611A1 (en) 2019-02-14
IL272137B2 (en) 2024-11-01
JP7079171B2 (ja) 2022-06-01
TW202246308A (zh) 2022-12-01
CN111164100A (zh) 2020-05-15
LT3661954T (lt) 2022-04-11
TWI798245B (zh) 2023-04-11
HRP20220404T1 (hr) 2022-05-27
IL312607A (en) 2024-07-01
CO2020001113A2 (es) 2020-05-15
PT3661954T (pt) 2022-04-14
CN111164100B (zh) 2024-03-12
ZA202001251B (en) 2025-04-30
ZA202210065B (en) 2025-04-30
ES2910969T3 (es) 2022-05-17
EP4029877A1 (en) 2022-07-20
BR112020002013B1 (pt) 2023-01-24
PE20200867A1 (es) 2020-08-31
UY37829A (es) 2019-01-31
JP7531545B2 (ja) 2024-08-09
TW202342501A (zh) 2023-11-01
AU2022228122A1 (en) 2022-09-29
TWI901940B (zh) 2025-10-21
AU2022228122B2 (en) 2024-05-02
WO2019028316A1 (en) 2019-02-07
SI3661954T1 (sl) 2022-05-31
MX2023013462A (es) 2023-12-15
CL2022000300A1 (es) 2022-09-23
KR20200035291A (ko) 2020-04-02
AU2018311079A1 (en) 2020-02-13
KR20220092652A (ko) 2022-07-01
SG11202000821SA (en) 2020-02-27
AU2018311079B2 (en) 2022-06-23
IL272137B1 (en) 2024-07-01
PE20250757A1 (es) 2025-03-13
PH12020500231A1 (en) 2021-01-11
CA3071376A1 (en) 2019-02-07
HUE058233T2 (hu) 2022-07-28
MA56289A (fr) 2020-06-10
IL312607B2 (en) 2025-08-01
EP3661954A1 (en) 2020-06-10
TW201920239A (zh) 2019-06-01
SA522432917B1 (ar) 2023-11-05
US20230381276A1 (en) 2023-11-30
CY1125429T1 (el) 2024-02-16
IL312607B1 (en) 2025-04-01
EP4029877B1 (en) 2024-01-17
MX2020001328A (es) 2020-03-20
JOP20200020B1 (ar) 2023-09-17
BR122021015266B1 (pt) 2023-01-24
SMT202200162T1 (it) 2022-05-12
TN2020000015A1 (en) 2021-10-04
SA520411230B1 (ar) 2022-11-08
JP2022116099A (ja) 2022-08-09
MA56289B1 (fr) 2022-04-29
US11541103B2 (en) 2023-01-03
TWI844073B (zh) 2024-06-01
CN118126157A (zh) 2024-06-04
CL2024002249A1 (es) 2025-02-21
JP2019033743A (ja) 2019-03-07
CL2020000252A1 (es) 2020-08-21
EP3661954B1 (en) 2022-02-09
IL272137A (en) 2020-03-31
CR20200099A (es) 2020-07-24
UA130113C2 (uk) 2025-11-19
KR102414120B1 (ko) 2022-06-28
DK3661954T3 (da) 2022-04-19
JOP20200020A1 (ar) 2020-02-02
BR112020002013A2 (pt) 2020-07-28

Similar Documents

Publication Publication Date Title
PL3661954T3 (pl) Muteiny interleukiny 21 i sposoby leczenia
IL280536A (en) Muscle targeting complexes and uses thereof
IL279897A (en) Fusosome compositions and uses thereof
EP4059510C0 (en) MODIFIED EXTRACELLULAR VESICLES AND THEIR USES
IL274844A (en) IL-2 mutants and their uses
EP3576765A4 (en) TARGETED ENGINEERING INTERFERON AND USES OF IT
EP3474820C0 (en) GLP-1 COMPOSITIONS AND ITS USES
DK3610005T3 (da) Peptidligase og anvendelse deraf
EP3781318A4 (en) EMULSIFIERS AND THEIR USES
EP3633034A4 (en) MODIFIED Cas9 PROTEIN AND USE THEREOF
DK3655401T3 (da) Tlr7/8-antagonister og anvendelser deraf
IL269490B (en) Surface treatment methods and compositions therefor
EP3893945A4 (en) CROMOGLYC ESTERS AND THEIR USES
EP3890028A4 (en) Display panel and terminal
EP3609504A4 (en) NEW OXABOROLE ANALOGUES AND USES OF THE LATEST
IL280150A (en) Graphene product and therapeutic uses thereof
IL270978B (en) Grape skin for use in the treatment of dysbiosis
EP3796877A4 (en) PACING AND TREATMENT DEVICE
EP3728562A4 (en) HEART MICROTISSUE AND ASSOCIATED USES
DK3788187T3 (da) Kombineret elektrorotations- og mikroekstruderingsanordning
ITUA20163417A1 (it) Fat and medical uses thereof
IL277458A (en) CD4 mutans and methods of using them
EP4034113A4 (en) THERAPEUTIC FORMULATIONS AND THEIR USES
EP3843690A4 (en) Personal care spray compositions and methods comprising trans-1-chloro-3,3,3-trifluoropropene
EP3746077A4 (en) PARENTERAL FORMULATIONS AND THEIR USES